Abstract: Background and Objectives: Leiomyosarcoma of skin (LMS) can be sub-classified on pathology appearances as Dermal or Subcutaneous. The aim of this study was to provide treatment recommendations for these uncommon tumours.
Methods: A retrospective review of all patients with dermal and subcutaneous leiomyosarcoma managed at the Peter MacCallum Cancer Centre, Australia from January 2003 to December 2018 was performed. Eighty-three patients were identified (64 dermal leiomyosarcoma, 19 subcutaneous leiomyosarcoma).
Results: Subcutaneous leiomyosarcoma were larger (median size 14 mm dermal, 49 mm subcutaneous, P = 0.01). No patient with a dermal leiomyosarcoma developed metastatic disease compared to 4 of the 19 subcutaneous leiomyosarcoma (5-year overall survivals, 98% and 88%, respectively, P = 0.03). The most common site of metastasis was to the lung. No difference in risk of local recurrence was apparent (5-year recurrence-free survivals were 85% and 78%, respectively, P = 0.17). Adjuvant radiotherapy was used in 16 (25%) dermal leiomyosarcoma patients and 13 (68%) subcutaneous leiomyosarcoma patients (P < 0.001). Local recurrence was uncommon in both tumour subtypes when patients received definitive surgical excision (minimum histological margins of 10 mm as per institutional protocol) regardless of whether radiotherapy was used. The 5-year local recurrence-free survival for dermal leiomyosarcoma treated with radiotherapy was 93% versus 83% without radiotherapy (P = 0.7) and for subcutaneous leiomyosarcoma was 69% and 100%, respectively (P = 0.9).
Conclusions: Dermal leiomyosarcoma have an excellent prognosis, particularly after definitive surgical excision with margins of at least 10 mm. Subcutaneous leiomyosarcoma has poorer outcomes and should be managed by wider excision and considered for adjuvant radiotherapy.
(© 2020 The Australasian College of Dermatologists.)
References: Aneiros-Fernandez J, Retamero J, Husein-Elahmed H et al. Primary cutaneous and subcutaneous leiomyosarcomas: evolution and prognostic factors. Eur. J. Dermatol. 2016; 26: 9-12.
Dahl I, Angervall L. Cutaneous and subcutaneous leiomyosarcoma. A clinicopathologic study of 47 patients. Pathol. Eur. 1974; 9: 307-15.
Fields JP, Helwig EB. Leiomyosarcoma of the skin and subcutaneous tissue. Cancer 1981; 47: 156-69.
Phelan JT, Sherer W, Mesa P. Malignant smooth-muscle tumors (Leiomyosarcomas) of soft-tissue origin. New Engl. J. Med. 1962; 266: 1027-30.
Farshid G, Pradhan M, Goldblum J et al. Leiomyosarcoma of somatic soft tissues: a tumor of vascular origin with multivariate analysis of outcome in 42 cases. Am. J. Surg. Pathol. 2002; 26: 14-24.
Leboit P, Burg G, Weedon D. Pathology and Genetics of Skin Tumours. Soft tissue tumours (2006).
Jensen M, Jensen O, Michalski W et al. Intradermal and subcutaneous leiomyosarcoma: a clinicopathological and immunohistochemical study of 41 cases. J. Cutan. Pathol. 1996; 23, 458-63.
R Core Team. R: A language and environment for statistical computing. [Computer software]. (2016). Retrieved from https://www.R-project.org.
Liao W-C, Wang Y-C, Ma H. Cutaneous leiomyosarcoma: the clinical experience of taipei veterans general hospital revisited. Ann. Plas. Surg. 2017; 78: S47-51.
Deneve JL, Messina JL, Bui MM et al. Cutaneous leiomyosarcoma: treatment and outcomes with a standardized margin of resection. Cancer Control 2013; 20: 307-12.
Massi D, Franchi A, Alos L et al. Primary cutaneous leiomyosarcoma: clinicopathological analysis of 36 cases. Histopathology 2010; 56: 251-62.
Pijpe J, Broers GH, Plaat BE et al. The relation between histological, tumor-biological and clinical parameters in deep and superficial leiomyosarcoma and leiomyoma. Sarcoma 2002; 6, 105-110.
Kaddu S, Beham A, Cerroni L et al. Cutaneous leiomyosarcoma. Am. J. Surg. Pathol. 1997; 21: 979-87.
Hornick JL, Fletcher CD. Criteria for malignancy in nonvisceral smooth muscle tumors. Ann. Diagn. Pathol. 2003; 7: 60-66.
Hall BJ, Grossmann AH, Webber NP et al. Atypical intradermal smooth muscle neoplasms (formerly cutaneous leiomyosarcomas): case series, immunohistochemical profile and review of the literature. Appl. Immunohisto M. M. 2013; 21, 132-38.
Winchester DS, Hocker TL, Brewer JD, et al. Leiomyosarcoma of the skin: clinical, histopathologic, and prognostic factors that influence outcomes. J. Am. Acad. Dermatol. 2014; 71: 919-25.
Fauth CT, Bruecks A, Temple W et al. Superficial leiomyosarcoma: a clinicopathologic review and update. J. Cutan. Pathol. 2010; 37: 269-76.
Kraft S, Fletcher CD. Atypical intradermal smooth muscle neoplasms: clinicopathologic analysis of 84 cases and a reappraisal of cutaneous ‘leiomyosarcoma’. Am. J. Surg. Pathol. 2011; 35: 599-607.
Stout A, Hill WT. Leiomyosarcoma of the superficial soft tissues. Cancer 1958; 11: 844-54.
Bernstein S, Roenigk R. Leiomyosarcoma of the skin. Treatment of 34 cases. Dermatol. Surg. 22, 631-35 (1996).
Hashimoto H, Daimaru Y, Tsuneyoshi M et al. Leiomyosarcoma of the external soft tissues. A clinicopathologic, immunohistochemical, and electron microscopic study. Cancer 1986; 57: 2077-88.
Processing Request
No Comments.